Posters

MyoRing implantation for the treatment of post-laser in situ keratomileusis keratectasia

Poster Details

First Author: M.Macsek AUSTRIA

Co Author(s):    A. Ettl   A. Daxer                 

Abstract Details

Purpose:

To evaluate the possibility of the implantation of a MyoRing (DIOPTEX GmbH, Austria) for the treatment of post-laser in situ keratomileusis (LASIK) keratectasia.

Setting:

Private refractive surgery center, Wels, Austria.

Methods:

This retrospective case report series studied 3 eyes (2 patients) with post-LASIK keratectasia, who were treated with the implantation of a MyoRing. Preoperatively, 1 year postoperatively and 2 years postoperatively (data only available for one eye) the uncorrected distance visual acuity (UCDVA), the best corrected distance visual acuity (BCDVA) and the manifest refraction were assessed.

Results:

The mean logMAR UCDVA improved from 0,64 �Â�± 0,32 (SD) preoperatively to 0,21 �Â�± 0,23 after 1 year. Respectively the mean logMAR BCDVA improved from 0,35 �Â�± 0,13 to 0,05 �Â�± 0,07, the mean spherical equivalent from -3,38 �Â�± 4,71 diopters (D) to -1,08 �Â�± 1,36 D and the mean astigmatism from 1,58 �Â�± 1,01 D to 0 �Â�± 0 D. In one eye the MyoRing had to be replaced by another MyoRing different in size due to unsatisfactory postoperative visual acuity. No progression of the keratectasia and no intraoperative or postoperative complications occurred during the observed period.

Conclusions:

MyoRing implantation for the treatment of post-LASIK keratectasia appeared to improve the UCDVA, the BCDVA and the manifest refraction. Considering possible limitations of other surgical approaches yet described for this indication, with further study, this treatment option might prove to be an effective and save approach.

Financial Disclosure:

gains financially from product or procedure presented, has significant investment interest in a company producing, developing or supplying product or procedure presented